Results 81 to 90 of about 150,265 (357)

Western and dot immunoblotting analysis of viral antigens and antibodies: application to murine hepatitis virus. [PDF]

open access: yes, 1984
Viral proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred quantitatively to nitrocellulose by electroblotting in SDS-containing buffer.
Buchmeier, MJ, Knobler, RL, Talbot, PJ
core  

Reactivation of hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis [PDF]

open access: yes, 2019
Ocrelizumab is an anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS) that is closely related to rituximab. We describe a case of hepatitis B virus (HBV) reactivation in an MS patient with resolved HBV infection receiving ...
Altieri, Marta   +11 more
core   +1 more source

NIBV Induces Incomplete Autophagy via AMPK‐TFEB, Causing Kidney Injury in Chicks

open access: yesAdvanced Science, EarlyView.
This study reveals that NIBV can inhibit the nuclear translocation of TFEB by suppressing the expression of AMPK, leading to the blockade of autophagolysosomal functions, in turn increasing NIBV replication and triggering severe kidney injury in chicks.
Cheng Huang   +10 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

open access: yes, 2022
Hepatology, EarlyView.
Robert J. Fontana   +6 more
wiley   +1 more source

Acute hepatitis of non-specified etiology

open access: yesРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии, 2011
Aim of investigation. To estimate pathogenic and diagnostic value of detection of hepatotropic viruses components (DNA, RNA, antigens) and antiviral immune response at acute hepatitis of non-specified etiology by the methods of enzyme-linked immunoassay (
Ye. V. Tsyganova   +7 more
doaj  

Treating cancer as an infectious disease--viral antigens as novel targets for treatment and potential prevention of tumors of viral etiology. [PDF]

open access: yesPLoS ONE, 2007
Nearly 20% of human cancers worldwide have an infectious etiology with the most prominent examples being hepatitis B and C virus-associated hepatocellular carcinoma and human papilloma virus-associated cervical cancer. There is an urgent need to find new
Xing Guo Wang   +6 more
doaj   +1 more source

Multicohort Validation of Gut Microbiome Signatures for Cholangiocarcinoma Diagnosis and Functional Characterization of Bifidobacterium Pseudocatenulatum

open access: yesAdvanced Science, EarlyView.
This study analyzes gut bacteria in cholangiocarcinoma patients, revealing distinct microbial signatures that enable accurate disease detection. Species‐based diagnostic models achieved over 98% accuracy in identifying cholangiocarcinoma and distinguished it from other liver diseases. The research demonstrates that specific beneficial bacteria suppress
Benchen Rao   +18 more
wiley   +1 more source

Hepatitis B testing practices at a tertiary care centre and their associated costs: A retrospective analysis.

open access: yesPLoS ONE, 2019
BackgroundHepatitis B is a viral infection requiring specific serologic testing to diagnose the stage of the disease. There are many tests which can be ordered in a variety of combinations.
Alexander Lawandi   +2 more
doaj   +1 more source

The influence of HLA matching on cytomegalovirus hepatitis and chronic rejection after liver transplantation [PDF]

open access: yes, 1993
Previous findings in liver transplantation patients have raised the concept that HLA plays a dualistic role. HLA matching will reduce rejection but may augment MHC restricted cellular immune mechanisms of liver allograft injury. To evaluate this concept,
Demetris, AJ   +9 more
core   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

open access: yesAdvanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy